{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:39Z","timestamp":1793361819798,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/neuonc\/nos146","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T07:34:55Z","timestamp":1343460895000},"page":"1163-1170","source":"Crossref","is-referenced-by-count":170,"title":["Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas"],"prefix":"10.1093","volume":"14","author":[{"given":"Matthias A.","family":"Karajannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krysten","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette O.","family":"Nusbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsivia","family":"Hochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Golfinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Thomas","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,7,27]]},"reference":[{"issue":"8","key":"key\n\t\t\t\t20170508182228_NOS146C1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/sj.emboj.7600136","article-title":"E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases","volume":"23","author":"Qian","year":"2004","journal-title":"Embo J"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/excr.1996.0221","article-title":"Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion","volume":"226","author":"Takahashi","year":"1996","journal-title":"Exp Cell Res"},{"issue":"5","key":"key\n\t\t\t\t20170508182228_NOS146C3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J Cell Biol"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/mao.0b013e31815d4429","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy","volume":"29","author":"Doherty","year":"2008","journal-title":"Otol Neurotol"},{"issue":"16","key":"key\n\t\t\t\t20170508182228_NOS146C5","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"key\n\t\t\t\t20170508182228_NOS146C6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol"},{"issue":"41","key":"key\n\t\t\t\t20170508182228_NOS146C7","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"issue":"14","key":"key\n\t\t\t\t20170508182228_NOS146C8","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2165\/00003495-200767140-00008","article-title":"Lapatinib","volume":"67","author":"Dhillon","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2","volume":"278","author":"Gutmann","year":"1997","journal-title":"JAMA"},{"issue":"4","key":"key\n\t\t\t\t20170508182228_NOS146C10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00129492-200606000-00018","article-title":"The natural history of vestibular schwannoma","volume":"27","author":"Stangerup","year":"2006","journal-title":"Otol Neurotol"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"27","key":"key\n\t\t\t\t20170508182228_NOS146C12","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1200\/JCO.2010.28.4687","article-title":"Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170508182228_NOS146C13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1227\/01.neu.0000333303.79931.83","article-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II","volume":"62","author":"Harris","year":"2008","journal-title":"Neurosurg"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","article-title":"Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma","volume":"93","author":"Plotkin","year":"2009","journal-title":"J Neurooncol"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2011","journal-title":"Am J Med Genet A"},{"issue":"1\u20132","key":"key\n\t\t\t\t20170508182228_NOS146C16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchromb.2005.11.044","article-title":"Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS\/MS)","volume":"831","author":"Bai","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"key\n\t\t\t\t20170508182228_NOS146C17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"304","key":"key\n\t\t\t\t20170508182228_NOS146C18","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q J Med"},{"issue":"4","key":"key\n\t\t\t\t20170508182228_NOS146C19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2214\/ajr.165.4.7676998","article-title":"Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety","volume":"165","author":"Mautner","year":"1995","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"key\n\t\t\t\t20170508182228_NOS146C20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2005.036319","article-title":"Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes","volume":"43","author":"Evans","year":"2006","journal-title":"J Med Genet"},{"issue":"4","key":"key\n\t\t\t\t20170508182228_NOS146C21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"key\n\t\t\t\t20170508182228_NOS146C22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"issue":"11","key":"key\n\t\t\t\t20170508182228_NOS146C23","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","article-title":"Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation","volume":"21","author":"Mautner","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"key\n\t\t\t\t20170508182228_NOS146C24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"issue":"2","key":"key\n\t\t\t\t20170508182228_NOS146C25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J Neurooncol"},{"issue":"12","key":"key\n\t\t\t\t20170508182228_NOS146C26","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170508182228_NOS146C27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20170508182228_NOS146C28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-011-0601-8","article-title":"Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer","volume":"29","author":"Taskar","year":"2011","journal-title":"Pharm Res"},{"issue":"9","key":"key\n\t\t\t\t20170508182228_NOS146C29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ncponc1161","article-title":"Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications","volume":"5","author":"Tortora","year":"2008","journal-title":"Nature Clin Prac"},{"key":"key\n\t\t\t\t20170508182228_NOS146C30","article-title":"A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer","author":"Rugo","journal-title":"Breast Cancer Res Treat"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/14\/9\/1163\/16663906\/nos146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T05:10:13Z","timestamp":1642914613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nos146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,27]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,7,27]]},"published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nos146","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954071.793459744","asserted-by":"object"}]},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7,27]]}}}